Edema News and Research

RSS

Edema means swelling caused by fluid in your body's tissues. It usually occurs in the feet, ankles and legs, but it can involve your entire body.

Study: Generic nifedipine product not bioequivalent to Adalat XL

An extended release generic nifedipine product (Mylan-Nifedipine extended release 60 mg formerly Gen-Nifedipine extended release 60mg, Genpharm ULC) is not bioequivalent to the Canadian originator product, Adalat(R) XL(R), according to the results of a study recently published in the International Journal of Clinical Pharmacology and Therapeutics.

4 Feb 2010

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Patients with gastrointestinal stromal tumours (GIST) can now take action at an earlier stage of this rare form of cancer to reduce the risk of their disease returning following surgery. Novartis Pharmaceuticals Canada announced today that Gleevec* (imatinib mesylate) has received conditional approval by Health Canada for the adjuvant (post-surgical) treatment of adult patients who are at intermediate to high risk of disease recurrence following the surgical removal of GIST.

27 Jan 2010

Prometheus Laboratories executes commercialization agreement with Novartis

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a commercialization agreement with Novartis under which Prometheus acquired exclusive rights to distribute, promote and sell PROLEUKIN® (aldesleukin) in the United States.

27 Jan 2010

China Pharma Holdings announces completion of clinical trials for Candesartan

China Pharma Holdings, Inc., which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that the Company has completed clinical trials for Candesartan, an anti-hypertension drug, and submitted the generic drug production application to the SFDA.

21 Jan 2010

Results of two pivotal Phase III clinical trials with oral FTY720 published

Results of the TRANSFORMS and FREEDOMS studies, the two pivotal Phase III clinical trials with oral FTY720 (fingolimod), have been published in The New England Journal of Medicine, providing comprehensive evidence to support the efficacy and safety profile of this first-in-class therapy for multiple sclerosis (MS).

21 Jan 2010

ABC publishes Pycnogenol monograph

The nonprofit American Botanical Council (ABC) has just published a monograph summarizing selected scientific and clinical studies of Pycnogenol®, a patented dietary ingredient from French maritime pine bark.

21 Jan 2010

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

pSivida Corp., a leader in the development of tiny, sustained-release drug delivery technologies, with two of the only three ophthalmic sustained-release delivery products approved by the FDA for treatment of back of the eye diseases, announced that its chief executive officer, Dr. Paul Ashton, will discuss ocular drug delivery in diabetic retinopathy during a presentation at the 6th Annual Diabetes Conference in London, on Friday, January 22.

21 Jan 2010

Alcon to acquire U.S. rights to Sirion Therapeutics' Durezol and Zirgan

Alcon, the world’s leader in eye care, announced today that it will purchase the rights in the United States for two FDA-approved topical eye care products from Sirion Therapeutics, Inc. The two products purchased are Durezol™, a marketed ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, and Zirgan™, a recently approved antiviral for the treatment of acute herpetic keratitis (corneal ulcers).

18 Jan 2010

CDS Investigator Group identifies a new predictor for successful corneal transplant

A new predictor of cornea transplant success has been identified by the Cornea Donor Study (CDS) Investigator Group. New analysis of data from the 2008 Specular Microscopy Ancillary Study (SMAS), a subset of the CDS, found that the preoperative donor cell count of endothelial cells, previously considered to be an important predictor of a successful transplant, did not correlate with graft success.

12 Jan 2010

PhotoMedex, Galderma Laboratories enter into co-promotion agreement for photodynamic therapy application

PhotoMedex and Galderma Laboratories, L.P. have entered into a co-promotion agreement for Galderma’s photodynamic therapy application for the treatment of actinic keratoses (“AK”).

11 Jan 2010

AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection

AMAG Pharmaceuticals, Inc. today provided an update on the commercial launch of Feraheme® (ferumoxytol) Injection for intravenous (IV) use, including preliminary fourth quarter 2009 Feraheme net product revenues estimates, as well as an update on the Company’s international and label expansion efforts.

10 Jan 2010

3Sbio submits registrational clinical trial application for Feraheme injection

3SBio Inc., a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a registrational clinical trial to the Chinese State Food and Drug Administration ("SFDA") for Feraheme (ferumoxytol) Injection for intravenous use.

8 Jan 2010

RMEI and PIM sponsor medical education virtual lecture for physicians on HAE management

Hereditary angioedema (HAE) is a disease affecting between 4,000 and 10,000 people in the United States each year, causing recurrent attacks of intense localized edema. HAE can be both difficult to diagnose and difficult to treat.

7 Jan 2010

IBI initiates Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090

Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it has initiated its Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090 in patients undergoing cataract surgery.

6 Jan 2010

DSMB recommends Quark Pharmaceuticals to continue clinical study of QPI-1002

Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that the independent Data Safety Monitoring Board ("DSMB") recommended that QPI-1002 (I5NP) continue on to the next phase of clinical testing.

5 Jan 2010

VELCADE sNDA receives FDA approval

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

5 Jan 2010

iCo Therapeutics grants 725,000 stock options to directors, officers and employees

iCo Therapeutics Inc. - iCo Therapeutics (the "Company") announced today that on December 29, 2009 the Company granted a total of 725,000 stock options to directors, officers and employees of the Company.

31 Dec 2009

Remedies to alleviate foot pain during pregnancy

"Oh my aching feet" is a phrase you hear often from pregnant women. But are sore feet a symptom they just must deal with during pregnancy? According to the American College of Foot and Ankle Surgeons (ACFAS) the answer is "no." There are many remedies available to help alleviate foot pain.

30 Dec 2009

Steroids not superior to laser treatments for DME

Researchers led by specialists at the Johns Hopkins Wilmer Eye Institute have found that injecting a corticosteroid, triamcinolone, directly into the eye may slow the progression of proliferative diabetic retinopathy, a complication of diabetes that frequently leads to blindness.

27 Dec 2009

Positive results from Alimera Sciences' Iluvien FAME trial for DME

Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported top-line results from the month 24 readout of the FAME Study.

23 Dec 2009

Edema News and Research

Further Reading

Study: Generic nifedipine product not bioequivalent to Adalat XL

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Prometheus Laboratories executes commercialization agreement with Novartis

China Pharma Holdings announces completion of clinical trials for Candesartan

Results of two pivotal Phase III clinical trials with oral FTY720 published

ABC publishes Pycnogenol monograph

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

Alcon to acquire U.S. rights to Sirion Therapeutics' Durezol and Zirgan

CDS Investigator Group identifies a new predictor for successful corneal transplant

PhotoMedex, Galderma Laboratories enter into co-promotion agreement for photodynamic therapy application

AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection

3Sbio submits registrational clinical trial application for Feraheme injection

RMEI and PIM sponsor medical education virtual lecture for physicians on HAE management

IBI initiates Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090

DSMB recommends Quark Pharmaceuticals to continue clinical study of QPI-1002

VELCADE sNDA receives FDA approval

iCo Therapeutics grants 725,000 stock options to directors, officers and employees

Remedies to alleviate foot pain during pregnancy

Steroids not superior to laser treatments for DME

Positive results from Alimera Sciences' Iluvien FAME trial for DME

From surviving to thriving: a framework for long-term success in people with HIV

Kevin Broadbelt

Michael Stryker

Latest News